Statements (12)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:ATCCode |
none (as of 2024)
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
LYL797
|
| gptkbp:intendedUse |
treatment of solid tumors
|
| gptkbp:mechanismOfAction |
selective estrogen receptor degrader
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:target |
estrogen receptor alpha
|
| gptkbp:bfsParent |
gptkb:Lyell_Immunopharma
|
| gptkbp:bfsLayer |
7
|